成人特应性皮炎治疗管理:与银屑病及慢性荨麻疹的真实世界比较
该横断面研究于2017年5月利用单中心回顾性数据库,比较401例特应性皮炎、230例慢性荨麻疹及535例银屑病成人患者的治疗管理。特应性皮炎中73%为中重度,但仅8%接受系统治疗,远低于慢性荨麻疹的26%和银屑病的47%。结论提示中重度特应性皮炎系统治疗使用不足。
要点
- 特应性皮炎中73%为中重度,远高于慢性荨麻疹39%和银屑病17%。
- 仅8%特应性皮炎患者接受系统治疗,慢性荨麻疹26%,银屑病47%。
- 78%特应性皮炎患者完成治疗教育项目,慢性荨麻疹35%,银屑病3%。
核心结论
- 特应性皮炎治疗仍以局部治疗为主,仅少数符合系统治疗条件的中重度患者接受了系统治疗。
- 结果提示应推动中重度特应性皮炎更频繁地使用系统治疗药物。
研究设计与样本
- 2017年5月进行的横断面分析,采用单中心数据库的回顾性数据。
- 纳入401例特应性皮炎成人患者,并与230例慢性荨麻疹和535例银屑病患者比较。
- 分析内容包括流行病学、严重程度、治疗教育干预及系统治疗数据。
主要发现
- 特应性皮炎患者中73%为中重度,慢性荨麻疹为39%,银屑病为17%。
- 特应性皮炎患者中78%完成治疗教育项目,慢性荨麻疹为35%,银屑病为3%。
- 特应性皮炎患者中8%记录有系统治疗(包括生物制剂),慢性荨麻疹为26%,银屑病为47%。
临床怎么用
- 对中重度特应性皮炎成人患者,应评估系统治疗指征,避免仅依赖局部治疗。
- 可借鉴慢性荨麻疹和银屑病中较高的系统治疗使用率,优化特应性皮炎治疗策略。
局限性
- 研究为单中心回顾性横断面分析,数据来自2017年5月,可能存在选择偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The therapeutic options in atopic dermatitis rely on consensus-based guidelines, also established for psoriasis and chronic urticaria. However, the therapeutic approach in atopic dermatitis, especially in the moderate-to-severe forms of the disease, seems less aggressive than in psoriasis and in chronic urticaria with a less frequent use of systemic agents. OBJECTIVES: To compare in real-life conditions the therapeutic management of adults with atopic dermatitis with those with psoriasis and chronic urticaria. METHODS: A transversal analysis was performed in May 2017, using retrospective data from a monocentric database. Data on epidemiology, severity, therapeutic educational intervention and systemic treatments were analysed from 401 patients with atopic dermatitis, compared with data from 230 patients with chronic urticaria and 535 patients with psoriasis. RESULTS: A high proportion (73%) of atopic dermatitis patients presented with a moderate-to-severe form of the disease compared to only 39% of chronic urticaria and 17% of psoriasis patients. Most of atopic dermatitis patients (78%) had completed a therapeutic educational programme, while the adherence was lower in chronic urticaria (35%) and in psoriasis (3%) patients. A systemic treatment, including biologicals, was recorded in 8% of atopic dermatitis patients, while it concerned 26% and 47% of chronic urticaria and psoriasis patients, respectively. CONCLUSIONS: We confirmed that atopic dermatitis treatment mostly relies on topical treatments. Only a minority of moderate-to-severe atopic dermatitis patients who are eligible for a systemic treatment receive such therapy. This may suggest promoting a more frequent use of systemic agents in moderate-to-severe atopic dermatitis.
引用
- Pascal C, Maucort-Boulch D, Gilibert S, et al. Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. J Eur Acad Dermatol Venereol. 2020. PMID: 32119144. doi:10.1111/jdv.16329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。